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Abstract
Immunological heterogeneity has long been the major challenge in developing broadly ef-
fective vaccines to protect humans and animals against bacterial and viral infections. En-
terotoxigenic Escherichia coli (ETEC) strains, the leading bacterial cause of diarrhea in
humans, express at least 23 immunologically different colonization factor antigens (CFAs)
and two distinct enterotoxins [heat-labile toxin (LT) and heat-stable toxin type Ib (STa or
hSTa)]. ETEC strains expressing any one or two CFAs and either toxin cause diarrhea,
therefore vaccines inducing broad immunity against a majority of CFAs, if not all, and both
toxins are expected to be effective against ETEC. In this study, we applied the multiepitope
fusion antigen (MEFA) strategy to construct ETEC antigens and examined antigens for
broad anti-CFA and antitoxin immunogenicity. CFA MEFA CFA/I/II/IV [CVI 2014, 21(2):243-
9], which carried epitopes of seven CFAs [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4,
CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, was genetically
fused to LT-STa toxoid fusion monomer 3xSTaA14Q-dmLT or 3xSTaN12S-dmLT [IAI 2014,
82(5):1823-32] for CFA/I/II/IV-STaA14Q-dmLT and CFA/I/II/IV-STaN12S-dmLT MEFAs. Mice
intraperitoneally immunized with either CFA/I/II/IV-STa-toxoid-dmLT MEFA developed anti-
bodies specific to seven CFAs and both toxins, at levels equivalent or comparable to those
induced from co-administration of the CFA/I/II/IV MEFA and toxoid fusion 3xSTaN12S-dmLT.
Moreover, induced antibodies showed in vitro adherence inhibition activities against ETEC
or E. coli strains expressing these seven CFAs and neutralization activities against both tox-
ins. These results indicated CFA/I/II/IV-STa-toxoid-dmLT MEFA or CFA/I/II/IV MEFA com-
bined with 3xSTaN12S-dmLT induced broadly protective anti-CFA and antitoxin immunity,
PLOS ONE | DOI:10.1371/journal.pone.0121623 March 24, 2015 1 / 20
a11111
OPEN ACCESS
Citation: Ruan X, Sack DA, Zhang W (2015) Genetic
Fusions of a CFA/I/II/IV MEFA (Multiepitope Fusion
Antigen) and a Toxoid Fusion of Heat-Stable Toxin
(STa) and Heat-Labile Toxin (LT) of Enterotoxigenic
Escherichia coli (ETEC) Retain Broad Anti-CFA and
Antitoxin Antigenicity. PLoS ONE 10(3): e0121623.
doi:10.1371/journal.pone.0121623
Academic Editor: Richard E. Isaacson, University of
Minnesota, UNITED STATES
Received: October 17, 2014
Accepted: February 2, 2015
Published: March 24, 2015
Copyright: © 2015 Ruan et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: Financial support for this study was
provided by NIH R56AI101302, NIH 1R21AI109209,
PATH, and Kansas State University. The funders had
no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
and suggested their potential application in broadly effective ETEC vaccine development.
This MEFA strategy may be generally used in multivalent vaccine development.
Introduction
Virulence heterogeneity among bacterial and viral strains or isolates has long been one major
challenge in vaccine development. Like many other infectious pathogens, enterotoxigenic
Escherichia coli (ETEC) strains (i.e., E. coli producing heat-labile and heat-stable enterotoxins)
are immunologically heterogeneous. ETEC strains are the most common bacterial cause of di-
arrhea which continues to be the second leading cause of death in children younger than 5
years who live in developing countries and remains a major threat to global health [1,2]. These
ETEC strains express immunologically different colonization factor antigen (CFA) adhesins
and enterotoxins. CFA adhesins mediate bacterial attachment to host receptors and facilitate
colonization in host small intestines. Enterotoxins disrupt fluid and electrolyte homeostasis in
host small intestinal epithelial cells that leads to fluid hyper-secretion and diarrhea [3]. There-
fore, CFA adhesins and enterotoxins are recognized the major virulence determinants. There
are at least 23 CFA or CS (coli surface antigen) adhesins and two very distinct enterotoxins
characterized among ETEC strains isolated from humans with diarrhea [3–6]. Enterotoxins
produced by ETEC strains associated with human diarrhea are heat-labile toxin (LT) and heat-
stable toxin type Ib (STa, human-type STa, STh or hSTa). Although heat-stable toxin type Ia
(porcine-type STa, STp or pSTa) and heat-stable toxin type II (STb), together with LT and/or
STa, are occasionally detected in ETEC strains isolated from human diarrheal patients, pSTa
and STb toxins cause diarrhea only in animals [3]. Since ETEC strains expressing any one or
two CFA or CS adhesins and LT or STa enterotoxin cause diarrhea, developing broadly protec-
tive vaccines against ETEC diarrhea continues to be very challenging [7,8].
Anti-CFA antibodies specific to an individual CFA or antitoxin antibodies to LT were re-
ported to provide protection to human volunteers against homologous challenge [9–12], but
not against ETEC strains expressing immunologically heterogeneous CFAs or the STa toxin.
Early experimental vaccine studies showed that killed ETEC prototype strain H10407 (O78:
H11, LT+STa+CFA/I+) induced anti-CFA/I and anti-LT antibodies that protected volunteers
against challenge of strain H10407 or a homologous strain [13,14]. These observations led to a
conceptual ETEC vaccine, that is, an ETEC vaccine that should induce antibodies protecting
against multiple CFA adhesins and toxin LT [15]. Consequently, products that were the result
of mixing together a few strains that expressed several CFA adhesins and recombinant LT-B
subunit protein or the homologous cholera toxin B subunit (CT-B) were examined for protec-
tion against ETEC diarrhea. Experimental vaccines currently under development include two
oral whole-cell ETEC vaccine candidates, rCTB-CF and ACE527. The rCTB-CF consists of five
killed strains expressing six CFA adhesins plus recombinant CT-B subunit protein [16,17], and
the ACE527 is composed of three live attenuated E. coli strains that express five CFA adhesins,
one CFA subunit, and LT-B subunit [18,19]. Recombinant CT-B subunit was included in the
rCTB-CF product because anti-CT-B antibodies were shown to provide short-term protection
against LT-producing ETEC strains [20]. Field studies showed that the rCTB-CF vaccine in-
duced antibody responses and protected adults traveling from developed countries to ETEC
endemic countries against the risk of disease by 60% to 70% [16,17] or against moderate to se-
vere diarrhea [21]. This product, however, provided no protection to children, especially very
young children living in endemic areas against ETEC diarrhea, and caused some adverse effects
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in very young children when an adult dose was given orally [22,23]. In addition, it did not re-
duce the overall diarrhea rate among US adults traveling to Guatemala and Mexico [21]. The
live ACE527 product was found associated with some adverse effects in volunteer studies, but
the adverse effects were reduced or eliminated when a lower dose was given [24]. This ACE527
induced antibody responses to LT-B, CFA/I, CS3, and CS6 among adult volunteers, but pro-
tected against only the severity of diarrhea outcome from homologous challenge [18,25].
Although efforts have been undertaken to continuously improve current vaccine candidates
[24,26,27], these products might still be unable to provide truly broad protection against ETEC
diarrhea because they carry only LT-B or CT-B subunit antigen but no STa antigens to induce
antibodies against STa toxin. Anti-LT antibodies were found protective against ETEC strains ex-
pressing LT but not against ETEC strains expressing the heat-stable toxin [28,29]. Furthermore,
cocktail products require a relatively high oral dose to stimulate host immune responses against
individual CFA adhesins and LT. A high oral dose delivers many somatic antigens, particularly
lipopolysaccharide (LPS) which is thought to be the cause of the gastrointestinal side effects as-
sociated with these vaccine candidates, especially in young children [30], and may also mask
stimulation of host anti-CFA and anti-LT (or anti-CT) specific antibody responses [8,31].
Ideally, a vaccine should induce antibodies against all CFA adhesins and both toxins, partic-
ularly STa toxin. In fact ETEC strains producing STa as the only toxin are the frequent cause of
ETEC diarrhea in developing countries [32]. ETEC strains that produce STa with or without
LT are associated with over two-thirds of human ETEC diarrhea cases [5], and tend to cause
moderate to severe diarrhea more frequently [21,33]. Therefore, ETEC vaccines may also need
to induce protective anti-STa antibodies in order to provide broad protection against
ETEC diarrhea.
Although STa is poorly immunogenic because of its small size (19 amino acids), it is a very
potent enterotoxin. Thus, STa presents a problem for use as a potential immunogen because it
does not induce immunity following exposure and also causes disease unless inactivated
[34,35]. However, recent studies demonstrated that STa, when had a single amino acid substi-
tuted, was less or non-toxic; moreover, derived STa toxoids became immunogenic after being
genetically fused to a strongly immunogenic LT toxoid monomer (a single peptide consisting
of a mutated LT-A subunit and one LT-B subunit) [36,37]. LT-STa toxoid fusions that carried
different STa toxoids were found to induce neutralizing antibodies against both LT and STa
toxins [38].
To induce anti-CFA antibodies effectively protecting against heterogeneous CFA adhesins
is another challenge in ETEC vaccine development. A recent study showed that a single CFA/I/
II/IV multiepitope fusion antigen (MEFA) was constructed and this CFA/I/II/IV MEFA in-
duced antibodies cross protective against seven ETEC CFA adhesins, CFA/I, CFA/II (CS1,
CS2, CS3) and CFA/IV (CS4, CS5, CS6) [39]. However, although these seven CFA adhesins are
expressed by ETEC strains causing 70–80% of ETEC diarrhea cases [23], their prevalence varies
greatly at different geographic locations [40]. Thus, antibodies against these seven CFA adhe-
sins may still not be sufficient to effectively protect against ETEC diarrhea in some regions.
In contrast to CFA adhesins with variable prevalence geographically, LT and STa, alone or
together, are expressed by all ETEC strains that cause diarrhea in humans. But anti-toxin anti-
bodies without assistance from antibodies against CFA adhesins may be less effective against
ETEC diarrhea [41]. If the CFA/I/II/IV MEFA is combined with or further fused to an optimal
LT-STa toxoid fusion that induces protective antibodies against both toxins, the resultant prod-
uct should be able to induce immunity to provide even broader protection against ETEC diar-
rhea, since the antitoxin antibodies provide supplementary protection against ETEC strains
expressing these seven CFA adhesins and independent protection against the ETEC strains ex-
pressing the other CFA adhesins.
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To create a single antigen inducing antibodies broadly protecting against seven CFA adhe-
sins and both toxins and to explore potential application of such an antigen in ETEC vaccine
development, in this study we first genetically fused the CFA/I/II/IV MEFA gene [39] to a
LT-STa toxoid fusion gene [38] for a CFA/I/II/IV-STa-toxoid-dmLT MEFA and examined anti-
CFA and antitoxin immunogenicity in a murine model. We then evaluated the induced anti-
bodies for neutralization activities against adherence from these seven CFA adhesins and enter-
otoxicity of both toxins. In addition, we immunized mice with the CFA/I/II/IV MEFA
combined with toxoid fusion 3xSTaN12S-dmLT, and compared induced antigen-specific anti-
body responses with those induced by the CFA/I/II/IV-STaN12S-dmLT MEFA to assess wheth-
er genetic fusion affected antigenic property of the fused CFA adhesin and toxin antigen
components, thus enabling application of MEFA strategy for multivalent vaccine development.
Materials and Methods
Bacterial strains and plasmids
The E. coli strains and plasmids used in this study are listed in Table 1. ETEC strains deposited
at Johns Hopkins University, Washington University and the E. coli Reference Strain Center at
University of Gothenburg (Sweden), and two recombinant E. coli strains expressing CS1 and
Table 1. Escherichia coli strains and plasmids used in the study.
Strains Relevant properties Sources
BL21 F- ompT hsdS (rB
-, mB
-), gal dcm. GE Healthcare
H10407 O78:H11; CFA/I, LT, STa Johns Hopkins
Univ.
UM 75688 CS5/CS6, LT, STa Johns Hopkins
Univ.
E106 (E11881/9) CS4/CS6, LT, STa Univ. of
Gothenburg
E116 (E19446) CS3, LT, STa Univ. of
Gothenburg
2423. ETP98066 CS6, LT, STa Washington Univ.
THK38/pEU405 CS1 Emory Univ.
DH5α/pEU588 CS2 Emory Univ.
9175 pCFA/I/II/IV in BL21 [39]
9164 p3xSTaA14Q-tmLT in BL21 [37]
9318 p3xSTaN12S-dmLT in BL21 [38]
9208 pCFA/I/II/IV-STaA14Q-dmLT in BL21 this study
9401 pCFA/I/II/IV-STaN12S-dmLT in BL21 this study
Plasmids
pET28α Novagen
pEU405 CS1 Emory Univ.
pEU588 CS2 Emory Univ.
pCFA/I/II/IV CFA MEFA subunit gene in pET28α at NheI/EagI [39]
p3xSTaA14Q-tmLT 3xSTaA14Q-tmLT fusion gene in pET28α at NheI/EagI [37]
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CS2 adhesins (gifts from Dr. J. Scott at Emory University) [42,43] were used for CFA adhesin
extraction and in antibody adherence inhibition assays. CFA and CS fimbriae and non-fimbrial
outer membrane proteins were generally referred to as CFA adhesins in this study, and LT,
STa, and derived toxoids described were of human-type. Recombinant strains 9175 (CFA/I/II/
IV MEFA) [39] and 9164 (3xSTaA14Q-tmLTS63K/R192G/L211A) [37] were used as templates first
to construct the CFA/I/II/VI-STaA14Q-dmLT MEFA gene. Recombinant strain 9318
(3xSTaN12S-dmLTR192G/L211A) was included for the construction of CFA/I/II/VI-STaN12S-
dmLTMEFA, after 3xSTaN12S-dmLT was identified as the optimal LT-STa toxoid fusion in in-
ducing anti-STa antibody response [38]. E. coli BL21 (GE Healthcare, Piscataway, NJ) and vec-
tor pET28α (Novagen, Madison, WI) were used to express the CFA/I/II/VI-STa-toxoid-dmLT
MEFA proteins.
CFA/I/II/IV-STa-toxoid-dmLT MEFA gene construction
Splicing overlap extension (SOE) PCR was used to construct CFA/I/II/IV-STa-toxoid-dmLT
MEFA genes as described previously [34,37]. Briefly, two PCR products, the multiepitope
CFA/I/II/IV fragment and the STa-toxoid-dmLT toxoid fusion fragment, were overlapped for a
single open-reading-framed CFA/I/II/IV-STa-toxoid-dmLT chimeric gene (Fig. 1). The multie-
pitope CFA/I/II/IV fragment, which carried antigenic epitopes of seven CFA adhesins (CFA/I,
CFA/II, and CFA/IV), was amplified in a PCR with primers T7-F (5’-TAATACGACTCACTA-
TAGGG-‘3) and CFA-toxoid-R (5’- ACCAAAGGCTCCCAAAGTCATTACAAGAGATAC-
TACTCCTGA-‘3) using plasmid pCFA/I/II/IV [39] as the DNA template. The STa-toxoid-
dmLT toxoid fragment, which consisted of 2 copies of the STa-toxoid (between the LT-A1 and
LT-A2 peptides and at the LT-B C-terminus), dmLT-A (132–240 amino acids) and LT-B, was
amplified with primers CFA-toxoid-F (5’-GTAATGACTTTGGGAGCCTTTGGTGTGATT-
GATGAACGATTACATCGT-‘3) and T7-R (5’-TGCTAGTTATTGGTCAGGGGT-‘3). Two
different toxoid fusion fragments were generated by using plasmid p3xSTaA14Q-tmLT [37] and
plasmid p3xSTaN12S-dmLT [38] as the DNA template, respectively. Each amplified toxoid fu-
sion fragment was overlapped to the multiepitope CFA/I/II/IV fragment to generate CFA/I/II/
IV-STaA14Q-dmLT and CFA/I/II/IV-STaN12S-dmLT. CFA/I/II/IV-STaA14Q-dmLT and CFA/I/
II/IV-STaN12S-dmLT were further PCR amplified with primers T7-F and T7-R. Amplified
products were digested with NheI and EagI restriction enzymes (New England BioLabs, Ips-
wich, MA) and ligated into expression vector pET28α. Cloned CFA/I/II/IV-STa-toxoid-dmLT
chimeric genes were verified with DNA sequencing.
Expression, extraction and detection of CFA/I/II/IV-STa-toxoid-dmLT
MEFA proteins
E. coli strain BL21 was used to host plasmid carrying CFA/I/II/IV-STaA14Q-dmLT or CFA/I/II/
IV-STaN12S-dmLT chimeric gene to express two CFA/I/II/IV-STa-toxoid-dmLT MEFA proteins.
Each recombinant strain (from a single colony) was cultured in 5 ml Luria Bertani (LB) broth
supplemented with kanamycin (30μg/ml) at 37°C on a shaker (150 rpm). Overnight grown cul-
ture was added to 500 ml 2x YT (2x Yeast Extract Tryptone) medium broth for continued incu-
bation. Bacteria were induced with isopropyl-1-thio-β-D-galactoside (IPTG; 0.5 mM) after
culture optical density reached 0.5 at 600 nm (OD600), and were incubated for 4 more hours.
Bacterial culture was centrifuged at 5,000 X g for 20 min, and pellets were used to extract total
insoluble proteins (inclusion body fraction) using bacterial protein extraction reagent (B-PER,
in phosphate buffer; Pierce, Rockford, IL) by following the manufacturer’s protocol.
Recombinant CFA/I/II/IV-STa-toxoid-dmLT MEFA proteins tagged with six histidines were
further extracted to a purity of greater than 90% using Ni-nitrilotriacetic acid (NTA) agarose
CFA-Toxoid MEFA for ETEC Vaccine
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(QIAGEN, Valencia, CA). 6xHis-tagged fusion proteins were refolded using a Protein Refold-
ing kit by following the manufacturer’s protocols (Novagen, Madison, WI). Refolded 6xHis-
tagged proteins were dialyzed in 20 mM Tris-HCl buffer overnight at 4°C, and were concen-
trated (to 1–2 mg/ml) using Spectra/Por molecularporous membrane tubing (Spectrum Labo-
ratories Inc., Rancho Dominquez, CA) and polyethylene glycol compound (PEG; Sigma,
St. Louis, MO) as described previously [37,44].
Ten microliter each refolded CFA/I/II/IV-STa-toxoid-dmLT MEFA protein (10–20 μg) was
analyzed in 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
immune blot assays. Mouse anti-CFA/I, anti-CS1, anti-CS2, anti-CS3, anti-CS4, anti-CS5 and
Fig 1. Construction and detection of the CFA/I/II/IV-STa-toxoid-dmLTMEFA. (A) Construction of the CFA/I/II/IV MEFA. The most antigenic epitopes of the
CS1, CS2, CS3, CS4, CS5 and CS6 major structural subunits were embedded into CFA/I major subunit by replacing the CfaB surface-exposed but less
antigenic epitopes. (B) Construction of the 3xSTaN12S-dmLT toxoid fusion. Three copies of the STa toxoid STaN12S gene were genetically fused to the
monomeric dmLT (LTR192G/L211A) gene using SOE (splicing overlap extension) PCRs. (C) Construction of CFA/I/II/IV-STaN12S-dmLTMEFA. A substitution of
the first 150 amino acids of the 3xSTaN12S-dmLT (the N-terminal STaN12S and the first 131 amino acids of LT-A subunit) with the CFA/I/II/IV MEFA created
the CFA/I/II/IV-STaN12S-dmLTMEFA. Four linkers: LGA, GPVD, Gly-Pro linker GPGP, and L-linker were used for the construction. (D) Western blot to detect
the CFA/I/II/IV-STaN12S-dmLTMEFA protein with anti-CFA/I, anti-CS1, -CS2, -CS3, -CS4, -CS5, and anti-CS6 MAb hybridoma supernatant (1:100; provided
by Dr. AM Svennerholm), and rabbit anti-CT (1:3300; Sigma) and anti-STa antiserum (1:3300; provided by Dr. DC Robertson). Extracted MEFA proteins
separated in 12% PAGE gel were detected with each anti-adhesin MAb, anti-CT and anti-STa antiserum and IRDye-labeled goat anti-mouse IgG or anti-
rabbit IgG (1:5000; LI-COR). Lane (+) indicated the CFA/I/II/IV-STaN12S-dmLTMEFA proteins, whereas lane (-) of extracted total proteins of E. coli BL21 host
strain as the negative control. Lane M is the protein marker (in kilo Daltons; Precision Plus Protein pre-stained standards; Bio-Rad).
doi:10.1371/journal.pone.0121623.g001
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anti-CS6 monoclonal antibody hybridoma supernatant (in dilution of 1:100; provided by Dr.
AM Svennerholm) [39], rabbit anti-CT serum (1:3300; Sigma), and protein-A column-purified
rabbit anti-STa serum (1:3300; provided by Dr. DC Robertson) [34] were used as the primary
antibody. IRDye-labeled goat anti-mouse or anti-rabbit IgG (1:5000; LI-COR, Lincoln, NE)
was used as the secondary antibody. CFA/I/II/IV-STa-toxoid-dmLT MEFA proteins were de-
tected with a LI-COR Odyssey premium infrared gel imaging system (LI-COR).
Mouse immunization with CFA/I/II/IV-STa-toxoid-dmLT MEFA proteins
Mouse immunization studies complied with the Animal Welfare Act by following the 1996 Na-
tional Research Council guidelines [45], and were approved and supervised by a state veterinar-
ian and the Kansas State University Institutional Animal Care and Use Committee. Data
generated from this study are publicly available. Before being used in mouse immunization,
CFA/I/II/IV-STa-toxoid-dmLT MEFA proteins were verified non-toxic using T-84 cells and EIA
cAMP and cGMP kits (Assay Design, MI) as previously described [34,37,38].
Four groups of 6- to 8-week-old female BALB/c mice (Charles River Laboratories Interna-
tional, Inc., Wilmington, MA) were included in the immunization study. The first group of 8
mice was each injected intraperitoneally (i.p.) with 200 μg refolded CFA/I/II/IV-STaA14Q-
dmLTMEFA protein (in 200 μl 20 mM Tris-HCl) and 200 μl Freund’s complete adjuvant
(FCA; Sigma). The second group of 15 mice was each injected (i.p.) with 200 μg refolded CFA/
I/II/IV-STaN12S-dmLT MEFA protein (in 200 μl 20 mM Tris-HCl) with 200 μl FCA. The third
group of 16 mice was each co-administered (i.p.) with refolded CFA/I/II/IV MEFA protein and
3xSTaN12S-dmLT toxoid fusion protein produced previously [38,39]. To keep the molecule
copy numbers of CFA/I/II/IV and 3xSTaN12S-dmLT antigens equivalent to 200 μg CFA/I/II/
IV-STaN12S-dmLT (based on peptide lengths of the CFA/I/II/IV and the STaN12S-dmLT pep-
tides), 80 μg CFA/I/II/IV protein and 150 μg 3xSTaN12S-dmLT protein were mixed (in a total
of 200 μl 20 mM Tris-HCl) and used (with 200 μl FCA) to immunize each mouse in this co-ad-
ministration group. The fourth group of 9 mice was each injected (i.p.) with 200 μl Freund’s
complete adjuvant and 200 μl protein buffer 20 mM Tris-HCl as the negative control. Two
booster injections at the same doses as the primary immunization but with Freund’s incom-
plete adjuvant (FIA) were followed at a bi-week interval. In addition, a group of 5 mice was
each immunized (i.p.) with 200 μg CFA/I fimbriae which were heat-extracted from ETEC
H10407 and 200 μl Freund’s adjuvants (FCA in the primary and FIA in boosters) as the posi-
tive control for mouse anti-CFA/I antibody response.
Blood samples were collected from each mouse before the primary immunization and 10 to
12 days after each immunization to prepare serum samples. Serum samples were stored at
-80°C until use. On day 37 post primary immunization, mice were anesthetized with CO2
and exsanguinated.
Mouse anti-CFA and anti-toxin antibody titration
Anti-CFA/I and anti-CS1, -CS2, -CS3, -CS4/CS6, -CS5/CS6, and anti-STa and anti-LT IgG an-
tibodies in serum of each mouse were titrated as described previously [34,37–39]. Briefly, 500
ng CFA/I, CS1, CS2, CS3, CS4/CS6, and CS5/CS6 heat-extracted from ETEC field isolates or
recombinant E. coli strains [39] (Table 1), or 100 ng LT (List Biological Laboratories, Inc.,
Campbell, CA) were coated to each well of H2B plates (Thermo Scientific, Rochester, NY) to ti-
trate antibodies specific to each CFA and LT; whereas 10 ng STa-ovalbumin conjugates were
coated to each well of Costar plates (Corning Inc., Corning, NY) to titrate anti-STa IgG anti-
bodies. All serum samples were examined in triplicate. Horseradish peroxidase (HRP)-conju-
gated goat anti-mouse IgG (1:3300; Sigma) and 3,3’,5,5’-tetramethylbenzidine (TMB)
CFA-Toxoid MEFA for ETEC Vaccine
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Microwell Peroxidase Substrate System (2-C) (KPL, Gaithersburg, MD) were used to measure
optical density (OD) at the wavelength of 405 nm. Antibody titers were calculated from the
highest dilution of a serum sample that produced OD readings of> 0.3 above the background
readings and were shown in a log10 scale as previously described [36,38].
Anti-CFA antibody adherence inhibition assay
Mouse serum samples pooled from each group were examined for in vitro antibody adherence
inhibition activity against ETEC strains expressing CFA/I, CS3, CS4/CS6, CS5/CS6, or CS6 and
E. coli recombinant strains expressing CS1 or CS2, using Caco-2 cells (ATCC, #HTB-37) as
previously described [39]. ETEC or E. coli bacteria expressing CFA/I, CFA/II or CFA/IV adhere
to Caco-2 cells, whereas neutralizing anti-CFA antibodies in mouse serum samples block ad-
herence of these ETEC or E. coli bacteria to Caco-2 cells. Therefore, by mixing the mouse
serum and bacteria of each strain, incubating the mixture with Caco-2 cells, and counting the
bacteria adhered to the incubated cells, we were able to measure serum antibody adherence in-
hibition activities against ETEC or E. coli expressing these seven CFA adhesins. Briefly, Caco-2
cells were seeded and grown in 75 ml flask (Corning). After growth of confluence, Caco-2 cells
were transferred to each well of a 12-well tissue culture plate containing Dulbecco’s modified
Eagle’s medium (DMEM)-20% fetal bovine serum (FBS) (Fisher Thermo Scientific, Pittsburg,
PA), and grown to a confluent monolayer (7x105 per well). ETEC and E. coli bacteria, after
overnight growth on sheep blood agar plates at 37°C, were scraped off with cotton swabs and
were gently suspended in sterile PBS. One hundred microliters of each bacterial suspension
(3.5x106 bacteria; with a multiplicity-of-infection ratio set at five bacteria to one Caco-2 cell)
were incubated with 20 μl serum sample pooled from the mice in each group on a shaker (50
rpm) for 1 h at room temperature. The bacteria and serum mixture was brought to 300 μl with
PBS, and was added to each well containing the Caco-2 cells (in 700 μl cell culture medium).
After incubation in a CO2 incubator (5% CO2) for 1 h at 37°C, wells were gently washed with
PBS to remove non-adherent ETEC or E. coli bacteria. Washed Caco-2 cells were dislodged
through incubation with 0.25% trypsin (200 μl per well) in a CO2 incubator for 30 min at 37°C.
Dislodged Caco-2 cells (with adherent ETEC or E. coli bacteria) were collected by centrifuga-
tion (15,000 g for 10 min) and then suspended in 1 ml PBS. Suspensions were gently but well
mixed, serially diluted, and plated on LB plates. After overnight growth at 37°C, ETEC or E.
coli bacteria colony forming units (CFUs) were counted.
Anti-LT and anti-STa antibody neutralization assays
Serum samples pooled from mice in each group were also examined for in vitro antibody neu-
tralization activities against STa and CT using EIA cAMP and cGMP kits (Assay Design) and
T-84 cells. STa stimulates an increase of intracellular cyclic GMP levels and CT elevates intra-
cellular cAMP levels in T-84 cells. Neutralizing antitoxin antibodies neutralize enterotoxicity
thus prevent STa and CT from stimulating intracellular cGMP or cAMP. Therefore, by incu-
bating serum with the toxin, adding the mixture to T-84 cells, and measuring cGMP or cAMP
levels in the cells, we were able to evaluate neutralization activities of mouse serum IgG anti-
bodies against STa or CT. As described previously [34,36–38], 30 μl pooled serum sample of
each immunization group or the control group was incubated with 2 ng STa toxin or 10 ng CT
for 30 min at room temperature, and the serum/toxin mixture was added to T-84 cells. After
incubation in a CO2 incubator for 1 h (for STa to measure cGMP) or 3 h (for CT to measure
cAMP), T-84 cells were measured for intracellular cGMP or cAMP levels (pmol/ml) with EIA
cGMP or cAMP kit by following the manufacturer’s protocol (Assay Design). STa or CT alone
(without serum) was used as the control to show enterotoxicity in stimulation of cGMP or
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cAMP in T-84 cells, and culture medium only (without toxin or serum) was used to show a
baseline of intracellular cAMP or cGMP level in T-84 cells.
Statistical analysis
Data were analyzed using SAS for Windows, version 8 (SAS Institute, Cary, NC). Results were
presented as means ± the standard deviations. A Student’s t-test was used to compare different
treatment groups. Calculated p values of less than 0.05 were considered as significant when
treatment groups were compared using two-tailed distribution and two-sample unequal vari-
ance. In addition, the non-parametric Mood’s Median Test was carried out to assess differences
of antibody neutralization activities (cAMP and cGMP, pmol/ml) from serum samples of the
immunized group and the control group.
Results and Discussion
Constructed CFA/I/II/IV-STa-toxoid-dmLT MEFAs consisted of epitopes of
the seven CFA adhesins, two copies of the STa toxoid, and a part of the
dmLT monomer
The overlap of CFA/I/II/IV MEFA and the 3xSTaA14Q-dmLT or 3xSTaN12S-dmLT PCR ampli-
fied products yielded two CFA/I/II/IV-STa-toxoid-dmLT chimeric genes (Fig. 1). Two recombi-
nant strains, 9208 and 9401, were constructed to express two CFA/I/II/IV-STa-toxoid-dmLT
MEFA proteins. These two MEFA proteins differed only at the STa toxoid, with STaA14Q in
9208 and STaN12S in 9401 (Table 1). DNA sequencing showed each chimeric gene was a single
open reading frame coding a single 6xHis-tagged CFA/I/II/IV-STa-toxoid-dmLT protein. Each
fusion protein consisted of 20 amino acids from the pET28α vector including the 6xHis tag
(six histidines), the CFA/I/II/IV MEFA (150 amino acids) carrying epitopes of CFA/I and
CS1-CS6 major subunits (CfaB, CooA, CotA, CstH, CsaB, CsfA and CssA), two copies of STa
toxoid STaA14Q or STaN12S, 109 amino acids of dmLT-A subunit (132–240, at the C-terminus;
with R192G and L211A mutations) and one copy of the LT-B subunit (100 amino acids), and
four intra-peptide linkers (Fig. 1C). The first copy of the STa toxoid (without the stop codon)
with a ‘GPVD’ linker was located after the mutated 192th amino acid residue (Arg!Gly) of
the LT-A subunit, and the second STa toxoid (with the stop codon) with an L-linker was at the
C-terminus of the fusion protein.
Coomassie blue stained SDS-PAGE showed over 90% of the proteins extracted from strains
9208 and 9401 had a molecular mass of about 48 KDa, the expected size of the 6xHis-tagged
CFA/I/II/IV-STa-toxoid-dmLT MEFA protein. This 6xHis-tagged protein was recognized by
anti-CFA/I and anti-CS1, -CS2, -CS3, -CS4, -CS5, and anti-CS6 MAb hybridoma supernatant,
and rabbit anti-STa and anti-CT sera in Western blot assays (Fig. 1D).
CFA/I/II/IV-STa-toxoid-dmLT MEFA proteins were well tolerated and
immunogenic
T-84 cells incubated with 100 μg refolded fusion protein CFA/I/II/IV-STaA14Q-dmLT or CFA/
I/II/IV-STaN12S-dmLT showed no increase of intracellular cAMP and cGMP levels. That indi-
cated neither MEFA protein possessed detectable LT or STa enterotoxicity. In addition, female
adult mice did not display any noticeable adverse effects after i.p. immunization with either
CFA/I/II/IV-STa-toxoid-dmLT MEFA protein. Mice co-administered with the CFA/I/II/IV
MEFA protein and the 3xSTaN12S-dmLT toxoid fusion protein remained healthy and
acted normally.
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Mice immunized with CFA/I/II/IV-STaA14Q-dmLT or CFA/I/II/IV-STaN12S-dmLT devel-
oped immune responses to CFA/I, CS1, CS2, CS3, CS4/6, CS5/6, STa, and LT. Serum samples
of the mice immunized with fusion CFA/I/II/IV-STaA14Q-dmLT had anti-CFA/I, -CS1, -CS2,
-CS3, -CS4/6, -CS5/6, -STa, and anti-LT IgG titers (in log10) of 2.98±0.02, 2.92±0.06, 2.81
±0.07, 2.73±0.07, 2.84±0.03, 2.92±0.04, 2.40±0.75, and 3.19±0.01, respectively (Fig. 2). Serum
samples from individual mice immunized with fusion CFA/I/II/IV-STaN12S-dmLT also devel-
oped IgG antibody responses to CFA/I, CS1, CS2, CS3, CS4/6 and CS5/6 adhesins and both
toxins (Table 2). Serum of the mice i.p. immunized with the heat-extracted CFA/I fimbriae had
anti-CFA/I IgG titer of 2.95 ±0.01 (log10).
There were no IgG antibodies specific to CFA/I, CFA/II, CFA/IV, STa or LT detected in
the serum samples of the control mice or serum samples collected before the primary
immunization.
Fig 2. Mouse serum anti-adhesin and antitoxin IgG antibody titers. Anti-CFA/I, anti-CS1, -CS2, -CS3, -CS4/CS6 and anti-CS5/CS6, and anti-STa and
anti-LT IgG antibodies in the serum of each mouse immunized with CFA/I/II/IV-STaA14Q-dmLT MEFA protein (●) and the serum of each control mouse ()
were titrated in ELISAs. CFA/I, CS1, CS2, CS3, CS4/CS6, CS5/CS6 heat-extracted from E. coli or ETEC strains in Table 1 (500 ng per well of a 2HB plate),
STa-ovalbumin (10 ng per well of a Costar plate), or LT (List Biological Laboratories, Inc.; 100 ng per well of a 2HB plate) and HRP-conjugated goat-anti-
mouse IgG (1:3300; the secondary antibodies) were used to titrate IgG antibodies specific to CFA/I, CS1, CS2, CS3, CS4/6, CS5/6 and to STa and LT toxins,
respectively. The antibody titer was calculated from the highest dilution of a serum sample that produced an ELISA optical density of greater than 0.3 (above
the background) and presented in a log10 scale. Each dot represented a mouse IgG titer, and the bars indicated the mean titer of the group.
doi:10.1371/journal.pone.0121623.g002
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Mice immunized with CFA/I/II/IV-STaN12S-dmLT and mice co-immunized
with CFA/I/II/IV and 3xSTaN12S-dmLT fusions developed similar or
comparable levels of anti-CFA and antitoxin antibody responses
Serum samples of the mice immunized with CFA/I/II/IV-STaN12S-dmLT MEFA and the mice
co-immunized with CFA/I/II/IV and 3xSTaN12S-dmLT developed similar titers of IgG antibod-
ies to CS1, CS3, CS4/6, CS5/6 and LT (Table 2). Serum of the co-immunized mice (with CFA/
I/II/IV and 3xSTaN12S-dmLT antigens) had greater titers of anti-CFA/I (2.69±0.05 vs 2.63
±0.09; p = 0.04), anti-CS2 (2.53±0.08 vs 2.44±0.10; p = 0.01) and anti-STa (2.88±0.08 vs 2.50
±0.52; p = 0.01) IgG antibodies, compared to the serum of the mice immunized with CFA/I/II/
IV-STaN12S-dmLT MEFA.
Serum samples of the immunized mice were shown to inhibit adherence
of ETEC strains expressing CFA/I, CS3, CS4/CS6, CS5/CS6 or CS6
and E. coli strains expressing CS1 or CS2 to Caco-2 cells
Serum samples pooled from the mice co-immunized with CFA/I/II/IV and 3xSTaN12S-dmLT
exhibited significant inhibition activities against adherence of H10407 (CFA/I+LT+STa+), E116
(CS3+LT+STa+), E106 (CS4+CS6+LT+STa+), UM75688 (CS5+CS6+LT+STa+) and 2423/
ETP98066 (CS6+LT+STa+), and E. coli recombinant strains expressing CS1 adhesin or CS2
adhesins (Table 3). Serum sample pooled from the mice immunized with CFA/I/II/
IV-STaN12S-dmLT showed significant adherence inhibition activities against all examined
ETEC and E. coli strains except the recombinant E. coli strain expressing CS2.
Antibodies in serum samples of the immunized mice showed
neutralizing activities against STa toxin and CT in vitro
Pooled serum samples from mice immunized with CFA/I/II/IV-STaA14Q-dmLT or CFA/I/II/
IV-STaN12S-dmLT, or co-immunized with CFA/I/II/IV MEFA and 3xSTaN12S-dmLT showed
neutralization activity against both STa and CT. Intracellular cGMP levels in T-84 cells incubat-
ed with 2 ng STa toxin and the serum of the mice immunized with CFA/I/II/IV-STaA14Q-
dmLT, CFA/I/II/IV-STaN12S-dmLT, or CFA/I/II/IV combined with 3xSTaN12S-dmLT were 36.7
±20.7, 23.2±7.0, 0.31±0.42 (pmol/ml), respectively (Fig. 3). These cGMP levels were significantly
Table 2. Anti-CFA/I, -CS1, -CS2, -CS3, -CS4/CS5, and anti-CS5/CS6, and anti-STa and anti-LT IgG antibody titers (in log10; mean ± standard devia-
tion) detected in the serum of mice immunized with the CFA/I/II/IV-STaN12S-dmLT or co-immunized with the CFA/I/II/IV MEFA and the 3xSTaN12S-
dmLT toxoid fusion.
Mouse immunization groupsa Mean serum IgG titer (log10) ± stdev
anti-CFA/I anti-CS1 anti-CS2 anti-CS3 anti-CS4/6 anti-CS5/6 anti-STa anti-LT
CFA/I/II/IV- STaN12S-dmLT (n = 15) 2.63 ± 0.09 2.54 ± 0.04 2.44 ± 0.10 2.50 ± 0.09 2.58 ± 0.06 2.66 ± 0.03 2.50 ± 0.52 2.12 ± 0.30
CFA/I/II/IV and 3xSTaN12S-dmLT (n = 16) 2.69 ± 0.05 2.56 ± 0.05 2.53 ± 0.08 2.50 ± 0.06 2.59 ± 0.03 2.67 ± 0.05 2.88 ± 0.08 2.27 ± 0.13
p valuesb 0.04 0.33 0.01 0.97 0.58 0.58 0.01 0.10
a: Groups of mice immunized with CFA/I/II/IV-STaN12S-dmLT MEFA, or co-immunized with CFA/I/II/IV and 3xSTaN12S-dmLT proteins. Anti-CFA/I, anti-
CS1, anti-CS2, anti-CS3, anti-CS4/CS5 and anti-CS5/CS6, and anti-STa and anti-LT IgG in serum sample of each immunized mouse was titrated by
ELISAs using heat-extracted adhesin (500 ng adhesin per well of 2HB plates), STa conjugates (10 ng STa-ovalbumin conjugates per well of CoStar
plates) and LT (100 ng LT per well of 2HB plates) as the coating antigen (in triplicates) and HRP-conjugated goat anti-mouse IgG (1:3300; Sigma) as the
secondary antibodies. IgG titers (in log10) were expressed in means ± standard deviation.
b: p values were calculated by using a Student t test comparing mouse antibody titers in each group (15 mice immunized with CFA/I/II/IV-STaN12S-dmLT,
16 mice co-immunized with CFA/I/II/IV and 3xSTaN12S-dmLT).
doi:10.1371/journal.pone.0121623.t002
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lower than the cGMP levels in T-84 cells incubated with 2 ng STa toxin and serum of the control
mice (80.7±7.3; p = 0.007,<0.001,<0.001 in Student’s t-test, and p<0.01,<0.001,<0.001 in
Mood’s Median Test) or the serum collected from pre-immunized mice (75.1±11.2; p = 0.03,
<0.001,<0.001 in Student’s t-test, and p<0.01,<0.001,<0.001 in Mood’s Median Test). The
cGMP level in T-84 cells incubated with 2 ng STa toxin alone was 78.7±7.2 pmol/ml.
The cAMP levels in T-84 cells incubated with CT (10 ng) and the pooled serum sample of
mice immunized with CFA/I/II/IV-STaA14Q-dmLT, CFA/I/II/IV-STaN12S-dmLT, or CFA/I/II/
IV co-immunized with 3xSTaN12S-dmLT were 14.4±0.51, 12.8±0.76, and 7.7±2.4 pmol/ml, re-
spectively (Fig. 4). These cAMP levels were significantly lower than those in cells incubated
with the toxin alone (53.7±1.3; p<0.01 in Student’s t-test and Mood’s Median Test) or with the
toxin and the serum sample of the control mice (40.1±6.5; p<0.01 in Student’s t-test and
Mood’s Median Test).
Results from this study showed that CFA/I/II/IV-STaA14Q-dmLT and CFA/I/II/IV-STaN12S-
dmLTMEFAs retained anti-CFA and antitoxin antigenicity as both induced antibody re-
sponses to seven heterogeneous ETEC CFA adhesins and LT and STa toxins. That suggested
potential application of CFA/I/II/IV-STa-toxoid-dmLT MEFAs in development of broadly pro-
tective ETEC vaccines. Vaccines inducing anti-CFA antibodies to broadly prevent ETEC ad-
herence and colonization and also antitoxin antibodies to neutralize both LT and STa toxins
are expected to be broadly effective against ETEC diarrhea. To develop a vaccine carrying rep-
resentative antigens of all or even a majority of the 23 characterized CFA adhesins and also two
toxins is an unreachable goal currently. But it appears feasible to develop a vaccine protecting
against ETEC strains that cause a majority of clinical cases including moderate to severe cases.
Vaccine candidates currently under development carry antigens of up to six CFA adhesins and
CT-B or LT-B subunit, but they do not induce anti-STa immunity and also require a high oral
delivery dose with excessive amount of somatic antigen. These vaccine candidates would have
to include additional strains to deliver additional CFAs and STa antigens in order to induce
Table 3. Results of in vitro antibody adherence inhibition assaysa, using serum samples of mice immunized with CFA/I/II/IV-STaN12S-dmLT, co-ad-
ministrated with CFA/I/II/IV MEFA and toxoid fusion 3xSTaN12S-dmLT, or the negative control mice. The number of ETEC or E. coli bacteria adhered
to Caco-2 cells was used to indicate activity of anti-CFA antibodies against bacteria adherence.
Mouse serumb CFA/I/II/IV-STaN12S-dmLT CFA/I/II/IV + 3xSTaN12S-dmLT control
Bacteria (CFUs)
H10407; CFA/I, LT, STa (x104) 14.4 ± 14.8 pc = 0.0018 39.7 ± 9.6 p = 0.017 107.5 ± 9.2
THK38/pEU405; CS1 (x103) 18.3 ± 7.7 p = 0.012 20.7 ± 11.6 p = 0.003 77 ± 7.1
DH5a/pEU588; CS2 (x103) 13.5 ± 4.8 p = 0.28 7.5 ± 4.5 p = 0.017 16.5 ± 2.1
E116; CS3, LT, STa (x103) 129 ± 49.9 p = 0.003 86 ± 49.6 p <0.001 235 ± 7.1
E106; CS4/CS6, LT, STa (x104) 15.6 ± 3.3 p < 0.001 26.7 ± 3.9 p < 0.001 125 ± 0
UM 75688; CS5/CS6, LT, STa (x103) 59.5 ± 27.3 p = 0.029 55 ± 35.2 p = 0.025 110 ± 14.1
ETP98066; CS6, LT, STa (x104) 45.3 ± 28.6 p<0.001 53.3 ± 27.1 p<0.001 201.2 ± 29.5
a: ETEC ﬁeld isolates and E. coli recombinant strains expressing CFA/I, CS1, CS2, CS3, CS4/CS6, CS5/CS6 and CS6 (3.5x106 CFUs) were individually
incubated with serum samples (20 μl) pooled from mice in the group immunized with CFA/I/II/IV-STaN12S-dmLT, co-immunized with the CFA/I/II/IV MEFA
and 3xSTaN12S-dmLT, or the control mice on a shaker (50 rpm) for 1 hour at room temperature. The serum-bacteria mixture was added to Caco-2 cells
(7x105 cells; 1 ml ﬁnal volume) and incubated in a CO2 incubator for 1 h. After washing off non-adherent bacteria, ETEC or E. coli bacteria adhered to
Caco-2 cells (in 1 ml PBS) were serial diluted, plated, cultured overnight, and counted (CFUs).
b: serum samples pooled from mice of the group immunized the CFA/I/II/IV-STaN12S-dmLT, the group co-immunized with CFA/I/II/IV and 3xSTaN12S-
dmLT, or the control group. These serum samples were used in the antibody adherence inhibition assay.
c: p values were calculated by using a Student t test comparing numbers of ETEC or E. coli bacteria adhered to the Caco-2 cells incubated with mouse
serum of each immunization group vs. bacteria adherent to the cells treated with serum of the control group.
doi:10.1371/journal.pone.0121623.t003
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broader anti-CFA and antitoxin antibody responses. But inclusion of additional strains would
require an even higher oral dose leading to potentially greater side effects.
A vaccine with fewer strains, or ideally a single strain, to express multiple CFA adhesins and
LT and STa toxins (or antigenic elements of these CFA adhesins and toxins) could overcome
the difficulties encountered by the cocktail vaccine candidates. Recently, we demonstrated that
a single CFA/I/II/IV MEFA carrying epitopes of seven CFA adhesins [CFA/I, CFA/II (CS1,
CS2, CS3) and CFA/IV (CS4, CS5, CS6)] induced antibodies broadly inhibiting adherence of
ETEC and E. coli strains expressing these seven CFA adhesins [39]. Protection against these
seven CFA adhesins can potentially protect against ETEC strains associated with 70% to 80%
of ETEC diarrhea cases [23,40] and also the moderate to severe cases [46]. Unlike cocktail vac-
cine candidates, this CFA/I/II/IV MEFA was expressed as a single protein by a single E. coli
strain, and for the first time induced antibody responses in mice protecting against all seven
Fig 3. Mouse serum in vitro antibody neutralization activity against STa toxin. Intracellular cyclic GMP
concentration (pmol/ml) in T-84 cells incubated with STa toxin and mouse serum was measured with an EIA
cGMP ELISA kit (Assay Design) and was used to indicate anti-STa antibody neutralizing activity. STa toxin
elevates intracellular cGMP in T-84 cells, whereas neutralizing anti-STa antibodies neutralize the toxin and
prevent STa from stimulating cGMP, thus a lower cGMP concentration indicates a stronger neutralization
activity of anti-STa antibodies. The serum sample (30 μl; in a final dilution of 1:33.3) pooled from each group
of mice immunized with CFA/I/II/IV-STaA14Q-dmLT or CFA/I/II/IV-STaN12S-dmLT, co-immunized with CFA/I/II/
IV and 3xSTaN12S-dmLT, the control group, or the serum sample collected prior to immunization was
incubated with STa toxin (2 ng, in 150 μl cell culture medium) for 30 min at room temperature, and the serum-
toxin mixture was added to T-84 cells (1 ml of final volume with cell culture medium). Intracellular cGMP
concentration in T-84 cells was measured after 1 hour incubation at a CO2 incubator, with the mean cGMP
and standard deviation (from four to six replicates) of each group indicated as columns and bars. The cGMP
levels in T-84 cells cultured with cell culture medium alone (without STa toxin or serum; no STa toxicity) or
with STa toxin in culture medium (without serum; STa toxicity) were used as controls.
doi:10.1371/journal.pone.0121623.g003
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CFA adhesins. Products developed from this CFA/I/II/IV MEFA can be formulated and ad-
ministrated at a regular or lower dose, thus will eliminate the risk of adverse effects associated
with the cocktail vaccine candidates. In addition, using a peptide or epitopes instead of an en-
tire adhesin as the antigen may have advantage. A peptide from an adhesin subunit can be
more effective in inducing adhesin-specific antibody responses. Experimental vaccines carrying
intact F18 fimbriae, physically purified (as a subunit vaccine) or expressed by a live E. coli strain
(as a live vaccine), were unable to induce effective antibody responses to protect pigs against
F18-fimbrial ETEC challenge [47,48]; however, a small peptide from the minor subunit of the
F18 fimbrial adhesin was shown to induce strongly protective antibodies against this F18 adhe-
sin [44,49]. Data from this study showed that mice immunized with the CFA/I/II/IV MEFA
Fig 4. Mouse serum in vitro antibody neutralization activity against cholera toxin (CT). Intracellular cAMP concentrations (pmol/ml) in T-84 cells
measured with an EIA cAMP ELISA kit (Assay Design) were used to indicate anti-LT antibody neutralizing activity. Neutralizing anti-LT antibodies neutralize
CT toxin and prevent CT from stimulating cAMP in T-84 cells, thus resulting in a lower intracellular cAMP level. The serum sample (30 μl; in a final dilution of
1:33.3) pooled from each group of mice immunized with CFA/I/II/IV-STaA14Q-dmLT or CFA/I/II/IV-STaN12S-dmLT, co-immunized with CFA/I/II/IV and
3xSTaN12S-dmLT, or the control group was incubated with CT toxin (10 ng, in 150 μl cell culture medium) for 30 min at room temperature, and the serum-toxin
mixture was added to T-84 cells (1 ml of final volume with cell culture medium). Intracellular cAMP concentration (pmole/ml) in T-84 cells was measured after
3 hour incubation at a CO2 incubator, with the mean cAMP and standard deviation (from four to six replicates) of each group indicated as columns and bars.
The cAMP levels in T-84 cells incubated with cell culture medium alone (without CT or serum; no CT toxicity) or with CT in culture medium (without serum; CT
toxicity) were also measured as references.
doi:10.1371/journal.pone.0121623.g004
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(co-administrated with the toxoid fusion) or the CFA/I/II/IV-STa-toxoid-dmLT that carried a
part of the CFA/I major subunit peptide developed a similar anti-CFA/I IgG titer as mice im-
munized with CFA/I fimbriae.
We reported recently that a STa toxoid, such as STaA14Q or STaN12S, can be genetically
fused to a monomeric LT toxoid peptide and the resultant LT-STa toxoid fusions elicited anti-
bodies neutralizing STa and LT toxins [37,38]. Results from the toxoid fusion and the CFA/I/
II/IV MEFA studies led us to believe that a single CFA/I/II/IV-STa-toxoid-dmLT MEFA could
induce broad anti-CFA and antitoxin antibody responses and can be potentially used for devel-
opment of a broadly protective ETEC vaccine. Data from the present study showed mice im-
munized with CFA/I/II/IV-STaA14Q-dmLT or CFA/I/II/IV-STaN12S-dmLT developed antibody
responses to all seven adhesins and both toxins. That indicated that the CFA/I/II/IV-STa-toxoid-
dmLTMEFA retained antigenicity of individual CFA adhesins and toxins, and suggested po-
tential application of CFA/I/II/IV-STa-toxoid-dmLT MEFA in ETEC vaccine development.
Data from this study showed that mice immunized with the CFA/I/II/IV-STaN12S-dmLT
developed greater titer of anti-STa IgG antibodies (2.50±0.52; in log10) than mice immunized
with CFA/I/II/IV-STaA14Q-dmLT (2.40±0.75); also, serum antibodies induced by CFA/I/II/
IV-STaN12S-dmLT exhibited greater neutralizing activity against STa enterotoxicity (Fig. 3).
That confirmed STaN12S is the preferred toxoid for fusions to induce anti-STa antibody re-
sponse. However, it was noted that IgG antibody titers to all CFA adhesins and LT in serum of
the mice immunized with the CFA/I/II/IV-STaN12S-dmLT were found systematically lower
than those in the serum of mice immunized with CFA/I/II/IV-STaA14Q-dmLT. Given the fact
that the only difference between these two MEFA antigens was the different STa toxoid, these
two MEFA antigens should have induced similar titers of antibody responses to the CFAs and
LT. Future studies will be needed to explore whether different STa toxoids alter antigenic struc-
ture of CFA/I/II/IV-STa-toxoid-dmLT MEFAs.
Since CFA/I/II/IV-STaN12S-dmLT MEFA induced antibodies with greater neutralizing ac-
tivity against STa (compared to CFA/I/II/IV-STaA14Q-dmLT MEFA) and also significant ad-
herence inhibition against ETEC or E. coli strains expressing six of the seven adhesins, this
MEFA was evaluated for potential application in multivalent vaccine development. By compar-
atively examining antigen-specific antibody responses in mice immunized with the single
CFA/I/II/IV-STaN12S-dmLT MEFA and in mice immunized with a combination of CFA/I/II/
IV MEFA and toxoid fusion 3xSTaN12S-dmLT, we found that mice in the two immunization
groups developed similar levels of anti-CS1, -CS3, -CS4/6 and anti-CS5/6, and anti-LT IgG an-
tibody responses (Table 2). That suggested that the fusion process did not compromise antige-
nicity of a majority of the individual antigenic components. It was observed, however, that
mice co-immunized with CFA/I/II/IV MEFA and 3xSTaN12S-dmLT fusion developed moder-
ately greater titers of anti-CFA/I (2.69±0.05 vs 2.63±0.9; p = 0.04), anti-CS2 (2.53±0.08 vs 2.44
±0.10; p = 0.01) and anti-STa (2.88±0.08 vs 2.50±0.52; p = 0.01) serum IgG antibodies. The
negative effect on anti-CFA/I and anti-CS2 immunogenicity could be resulted from alteration
of the CFA/I and CS2 epitope antigenic topology in the CFA/I/II/IV-STaN12S-dmLT MEFA,
since the CFA/I epitope (159SGVVSLVMT167) and the CS2 epitope were located at the C-ter-
minus of the CFA/I/II/IV MEFA to which the toxoid fusion was fused. Future protein structure
studies may help to reveal if any structural alteration occurred. Since the anti-adhesin antibod-
ies induced by the CFA/I/II/IV-STaN12S-dmLT MEFA were able to significantly inhibit adher-
ence of ETEC H10407 strain but not against CS2 strain (Table 3), we may only need to
optimize the construction to enhance anti-CS2 immunogenicity. To relocate the CS2 epitope
toward the N-terminus or to extend the linker between CFA/I/II/IV MEFA and the toxoid fu-
sion may improve CS2 epitope presentation and anti-CS2 immunogenicity.
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Data from the study showed a lower anti-STa IgG antibody response in mice immunized
with CFA/I/II/IV-STaN12S-dmLT MEFA compared to the mice co-administrated with the
CFA/I/II/IV and 3xSTaN12S-dmLT (Table 2). That was not surprising because only two copies
of STaN12S were carried by CFA/I/II/IV-STaN12S-dmLT MEFA (versus three STaN12S toxoids
were carried by the 3xSTaN12S-dmLT used for co-administration). Additional copies of a STa
toxoid in a LT-STa toxoid fusion were shown to enhance anti-STa antigenicity [37]. That also
explained that only serum sample from the co-administrated mice was able to completely neu-
tralized 2 ng STa (Fig. 3). Had CFA/I/II/IV-STaN12S-dmLT MEFA carried three copies of
STaN12S, we would have observed a similar level of anti-STa antibody response and antibody
neutralization activity against STa from the serum of the immunized mice. Future studies to
modify the CFA/I/II/IV-STaN12S-dmLT MEFA to carry three copies of STaN12S, and to exam-
ine whether it induces the same level of anti-STa antibody response and more importantly anti-
bodies with similar neutralizing activity against STa as the combination of 3xSTaN12S-tmLT
and CFA/I/II/IV will be informative.
Data from the study also showed that serum of mice co-immunized with CFA/I/II/IV
MEFA and 3xSTaN12S-dmLT showed greater neutralization activity against CT (Fig. 4). In con-
trast to CFA/I/II/IV-STaA14Q-dmLT or CFA/I/II/IV-STaN12S-dmLT MEFA which contained
the last 109 amino acids of LT-A1, the co-administrated toxoid fusion 3xSTaN12S-dmLT car-
ried the entire LT-A1 peptide. That suggested the antibody response to the LT-A1 peptide
could play an important role in neutralizing against LT or CT toxin.
Although results from the current study suggested that a fusion of the CFA/I/II/IV MEFA
and the toxoid fusion did not significantly alter antigenicity of the carried adhesin and toxin
antigenic components, the combination of the CFA/I/II/IV MEFA and toxoid fusion
3xSTaN12S-dmLT seemed the better antigens for future ETEC vaccine development as these
two antigens induced greater titers of anti-STa, anti-CFA/I and anti-CS2 antibodies than the
single CFA/I/II/IV-STaN12S-dmLT MEFA. But a vaccine product derived from a single antigen
or a single strain decreases complexity and cost in product manufacture. If the CFA/I/II/
IV-STaN12S-dmLT MEFA, with modification to carry an additional copy of STaN12S and to
have anti-CS2 antigenicity enhanced, is safe and induces equivalent antibody responses to all
seven adhesins and both toxins as the combination of CFA/I/II/IV and 3xSTaN12S-dmLT, this
modified CFA/I/II/IV-STaN12S-dmLT MEFA should be the preferred antigen for ETEC
vaccine development.
It needs to point out that only intraperitoneal immunization route was used to examine
immunogenicity of the CFA/I/II/IV-STa-toxoid-dmLT MEFAs in this study. Future studies
using intradermal, intramuscular, subcutaneous or even oral route, and perhaps with different
adjuvants such as dmLT which is also an antigen to further induce neutralizing anti-LT anti-
bodies, will help us to characterize better the immunogenicity of a modified CFA/I/II/
IV-STaN12S-dmLT MEFA. In addition, fusion protein structure, protein integrity and stability,
and more importantly safety of this CFA/I/II/IV-STaN12S-dmLT MEFA, as well as the CFA/I/
II/IV MEFA and the 3xSTaN12S-dmLT (for co-administration), would have to be thoroughly
characterized before it can be assessed for ETEC vaccine development. Furthermore, animal
models including a piglet challenge model and a rabbit colonization model, and perhaps the
modified RITARD (removable intestine tie adult rabbit diarrhea) model, will be needed in pre-
clinical studies to evaluate protective efficacy of the induced anti-CFA and antitoxin immunity
against ETEC diarrhea prior to human volunteer studies or field trials. Additionally, despite of
results from a recent study indicated that anti-STa monoclonal and polyclonal antibodies had
no reactivity with guanylin and a very low reactivity with uroguanylin [50], anti-STa antibodies
induced by the toxoid fusion or CFA-toxoid MEFAs would need to be evaluated for cross reac-
tivity with guanylin and uroguanylin. This study, nevertheless, demonstrated that epitopes
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from multiple CFA adhesins and antigens from both toxins can be fused together as a single
MEFA protein to induce broadly protective antibody responses, and suggested potential appli-
cation of MEFA for effective ETEC vaccine development. In addition, as plasticity in MEFA
construction allows inclusion of additional antigens for even broader protection, this MEFA
approach perhaps can be generally used in effective vaccine development against diseases
caused by other immunologically heterogeneous pathogenic strains or isolates.
Conclusions
Results from this study indicated CFA/I/II/IV-STa-toxoid-dmLT MEFA or CFA/I/II/IV MEFA
combined with 3xSTaN12S-dmLT induced broadly protective anti-CFA and antitoxin immuni-
ty, and suggested their potential application in broadly effective ETEC vaccine development.
This MEFA strategy may be generally used in multivalent vaccine development.
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